Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Cortisone Shots Market

ID: MRFR/Pharma/3419-HCR
110 Pages
Vikita Thakur
Last Updated: May 15, 2026

Cortisone Shots Market Research Report Information: By Type (Articular or Joint Injections, Epidural Steroid Injection, Trigger Point Injection), Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Tendinitis, Allergic Reaction), End User - Global Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Cortisone Shots Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Orthopedic
      2. 4.1.2 Dermatology
      3. 4.1.3 Rheumatology
      4. 4.1.4 Pulmonology
      5. 4.1.5 Ophthalmology
    2. 4.2 Healthcare, BY Administration Route (USD Million)
      1. 4.2.1 Intra-articular
      2. 4.2.2 Intramuscular
      3. 4.2.3 Intradermal
      4. 4.2.4 Subcutaneous
    3. 4.3 Healthcare, BY Patient Demographics (USD Million)
      1. 4.3.1 Age Group
      2. 4.3.2 Gender
      3. 4.3.3 Health Status
      4. 4.3.4 Activity Level
    4. 4.4 Healthcare, BY Formulation Type (USD Million)
      1. 4.4.1 Aqueous
      2. 4.4.2 Suspension
      3. 4.4.3 Emulsion
    5. 4.5 Healthcare, BY Treatment Duration (USD Million)
      1. 4.5.1 Short-term
      2. 4.5.2 Long-term
      3. 4.5.3 Chronic
    6. 4.6 Healthcare, BY Region (USD Million)
      1. 4.6.1 North America
        1. 4.6.1.1 US
        2. 4.6.1.2 Canada
      2. 4.6.2 Europe
        1. 4.6.2.1 Germany
        2. 4.6.2.2 UK
        3. 4.6.2.3 France
        4. 4.6.2.4 Russia
        5. 4.6.2.5 Italy
        6. 4.6.2.6 Spain
        7. 4.6.2.7 Rest of Europe
      3. 4.6.3 APAC
        1. 4.6.3.1 China
        2. 4.6.3.2 India
        3. 4.6.3.3 Japan
        4. 4.6.3.4 South Korea
        5. 4.6.3.5 Malaysia
        6. 4.6.3.6 Thailand
        7. 4.6.3.7 Indonesia
        8. 4.6.3.8 Rest of APAC
      4. 4.6.4 South America
        1. 4.6.4.1 Brazil
        2. 4.6.4.2 Mexico
        3. 4.6.4.3 Argentina
        4. 4.6.4.4 Rest of South America
      5. 4.6.5 MEA
        1. 4.6.5.1 GCC Countries
        2. 4.6.5.2 South Africa
        3. 4.6.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Pfizer (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck & Co (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sanofi (FR)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Amgen (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 AbbVie (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Hikma Pharmaceuticals (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Mylan (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Teva Pharmaceutical Industries (IL)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY APPLICATION
    4. 6.4 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
    5. 6.5 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    6. 6.6 US MARKET ANALYSIS BY FORMULATION TYPE
    7. 6.7 US MARKET ANALYSIS BY TREATMENT DURATION
    8. 6.8 CANADA MARKET ANALYSIS BY APPLICATION
    9. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    10. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    11. 6.11 CANADA MARKET ANALYSIS BY FORMULATION TYPE
    12. 6.12 CANADA MARKET ANALYSIS BY TREATMENT DURATION
    13. 6.13 EUROPE MARKET ANALYSIS
    14. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
    15. 6.15 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    16. 6.16 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    17. 6.17 GERMANY MARKET ANALYSIS BY FORMULATION TYPE
    18. 6.18 GERMANY MARKET ANALYSIS BY TREATMENT DURATION
    19. 6.19 UK MARKET ANALYSIS BY APPLICATION
    20. 6.20 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
    21. 6.21 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    22. 6.22 UK MARKET ANALYSIS BY FORMULATION TYPE
    23. 6.23 UK MARKET ANALYSIS BY TREATMENT DURATION
    24. 6.24 FRANCE MARKET ANALYSIS BY APPLICATION
    25. 6.25 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    26. 6.26 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    27. 6.27 FRANCE MARKET ANALYSIS BY FORMULATION TYPE
    28. 6.28 FRANCE MARKET ANALYSIS BY TREATMENT DURATION
    29. 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION
    30. 6.30 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    31. 6.31 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    32. 6.32 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE
    33. 6.33 RUSSIA MARKET ANALYSIS BY TREATMENT DURATION
    34. 6.34 ITALY MARKET ANALYSIS BY APPLICATION
    35. 6.35 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    36. 6.36 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    37. 6.37 ITALY MARKET ANALYSIS BY FORMULATION TYPE
    38. 6.38 ITALY MARKET ANALYSIS BY TREATMENT DURATION
    39. 6.39 SPAIN MARKET ANALYSIS BY APPLICATION
    40. 6.40 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    41. 6.41 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    42. 6.42 SPAIN MARKET ANALYSIS BY FORMULATION TYPE
    43. 6.43 SPAIN MARKET ANALYSIS BY TREATMENT DURATION
    44. 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    45. 6.45 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    46. 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    47. 6.47 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE
    48. 6.48 REST OF EUROPE MARKET ANALYSIS BY TREATMENT DURATION
    49. 6.49 APAC MARKET ANALYSIS
    50. 6.50 CHINA MARKET ANALYSIS BY APPLICATION
    51. 6.51 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    52. 6.52 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    53. 6.53 CHINA MARKET ANALYSIS BY FORMULATION TYPE
    54. 6.54 CHINA MARKET ANALYSIS BY TREATMENT DURATION
    55. 6.55 INDIA MARKET ANALYSIS BY APPLICATION
    56. 6.56 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    57. 6.57 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    58. 6.58 INDIA MARKET ANALYSIS BY FORMULATION TYPE
    59. 6.59 INDIA MARKET ANALYSIS BY TREATMENT DURATION
    60. 6.60 JAPAN MARKET ANALYSIS BY APPLICATION
    61. 6.61 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    62. 6.62 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    63. 6.63 JAPAN MARKET ANALYSIS BY FORMULATION TYPE
    64. 6.64 JAPAN MARKET ANALYSIS BY TREATMENT DURATION
    65. 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    66. 6.66 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    67. 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    68. 6.68 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE
    69. 6.69 SOUTH KOREA MARKET ANALYSIS BY TREATMENT DURATION
    70. 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION
    71. 6.71 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    72. 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    73. 6.73 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE
    74. 6.74 MALAYSIA MARKET ANALYSIS BY TREATMENT DURATION
    75. 6.75 THAILAND MARKET ANALYSIS BY APPLICATION
    76. 6.76 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
    77. 6.77 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    78. 6.78 THAILAND MARKET ANALYSIS BY FORMULATION TYPE
    79. 6.79 THAILAND MARKET ANALYSIS BY TREATMENT DURATION
    80. 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION
    81. 6.81 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    82. 6.82 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    83. 6.83 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE
    84. 6.84 INDONESIA MARKET ANALYSIS BY TREATMENT DURATION
    85. 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION
    86. 6.86 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
    87. 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    88. 6.88 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE
    89. 6.89 REST OF APAC MARKET ANALYSIS BY TREATMENT DURATION
    90. 6.90 SOUTH AMERICA MARKET ANALYSIS
    91. 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION
    92. 6.92 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
    93. 6.93 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    94. 6.94 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE
    95. 6.95 BRAZIL MARKET ANALYSIS BY TREATMENT DURATION
    96. 6.96 MEXICO MARKET ANALYSIS BY APPLICATION
    97. 6.97 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
    98. 6.98 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    99. 6.99 MEXICO MARKET ANALYSIS BY FORMULATION TYPE
    100. 6.100 MEXICO MARKET ANALYSIS BY TREATMENT DURATION
    101. 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION
    102. 6.102 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    103. 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    104. 6.104 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE
    105. 6.105 ARGENTINA MARKET ANALYSIS BY TREATMENT DURATION
    106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE
    110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT DURATION
    111. 6.111 MEA MARKET ANALYSIS
    112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
    114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE
    116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT DURATION
    117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE
    121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT DURATION
    122. 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION
    123. 6.123 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    124. 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
    125. 6.125 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE
    126. 6.126 REST OF MEA MARKET ANALYSIS BY TREATMENT DURATION
    127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
    128. 6.128 RESEARCH PROCESS OF MRFR
    129. 6.129 DRO ANALYSIS OF HEALTHCARE
    130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
    133. 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    134. 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    135. 6.135 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    136. 6.136 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
    137. 6.137 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
    138. 6.138 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Million)
    139. 6.139 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE)
    140. 6.140 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Million)
    141. 6.141 HEALTHCARE, BY TREATMENT DURATION, 2024 (% SHARE)
    142. 6.142 HEALTHCARE, BY TREATMENT DURATION, 2024 TO 2035 (USD Million)
    143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.2.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.2.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.3.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.3.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.3.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.3.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.4.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.4.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.4.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.4.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.5.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.5.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.5.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.5.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.6.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.6.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.6.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.6.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.7.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.7.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.7.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.7.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.8.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.8.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.8.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.8.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.9.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.9.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.9.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.9.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.10.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.10.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.10.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.10.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.11.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.11.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.11.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.11.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.12.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.12.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.12.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.12.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.13.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.13.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.13.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.13.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.14.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.14.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.14.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.14.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.15.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.15.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.15.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.15.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.16.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.16.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.16.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.16.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.17.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.17.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.17.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.17.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.18.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.18.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.18.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.18.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.19.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.19.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.19.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.19.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.20.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.20.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.20.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.20.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.21.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.21.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.21.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.21.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.22.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.22.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.22.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.22.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.23.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.23.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.23.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.23.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.24.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.24.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.24.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.24.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.25.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.25.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.25.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.25.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.26.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.26.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.26.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.26.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.27.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.27.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.27.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.27.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.28.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.28.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.28.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.28.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.29.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.29.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.29.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.29.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.30.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
      3. 7.30.3 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Million)
      4. 7.30.4 BY FORMULATION TYPE, 2025-2035 (USD Million)
      5. 7.30.5 BY TREATMENT DURATION, 2025-2035 (USD Million)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

  • Orthopedic
  • Dermatology
  • Rheumatology
  • Pulmonology
  • Ophthalmology

Healthcare By Administration Route (USD Million, 2025-2035)

  • Intra-articular
  • Intramuscular
  • Intradermal
  • Subcutaneous

Healthcare By Patient Demographics (USD Million, 2025-2035)

  • Age Group
  • Gender
  • Health Status
  • Activity Level

Healthcare By Formulation Type (USD Million, 2025-2035)

  • Aqueous
  • Suspension
  • Emulsion

Healthcare By Treatment Duration (USD Million, 2025-2035)

  • Short-term
  • Long-term
  • Chronic

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓